EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis

Jeayoung Park iD, Spyridon Ntelis, Elvina Yunasan, Katherine D Downton, Terry Cheuk-Fung Yip iD, Kashif M Munir iD, Nowreen Haq iD

The Journal of Clinical Endocrinology & Metabolism · 21.12.2023 · 109 (1) · 279-292

DOI: 10.1210/clinem/dgad471 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 10.08.2023. Verfasst von Jeayoung Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Concomitant obesity is common among patients with type 1 diabetes mellitus (T1DM), yet adjunctive therapy options are scarce.

Objective

We assess the efficacy and adverse outcomes of glucagon-like peptide 1 (GLP-1) analogues when used as adjunctive therapy for T1DM.

Method

PubMed, EMBASE, Cochrane Central, and Scopus databases were searched for randomized controlled trials up to December 2022. Efficacy outcomes were A1c level, body weight, and total daily insulin (TDI) after ≥12 weeks of GLP-1 therapy. We also assessed 12 different adverse outcomes. Subgroup analysis was done for newly diagnosed or C-peptide positive (C-pos) patients. We report the certainty of evidence based on the GRADE assessment tool.

Results

A total of 24 studies using 4 different GLP-1 analogues with a total of 3377 patients were included. Liraglutide had the most substantial evidence with effect sizes on A1c (−0.09%/mg), weight (−2.2 kg/mg), and TDI (−4.32 IU/mg). Liraglutide dose was the greatest predictor of greater average weight loss and TDI decrease but was associated with higher odds of nausea (OR 6.5; 95% CI, 5.0-8.4) and ketosis (OR 1.8; 95% CI, 1.1-2.8). Odds of severe (OR 0.67; 95% CI, 0.43-1.04) or symptomatic hypoglycemia (OR 0.89; 95% CI, 0.53-1.51) were not significantly elevated. Among C-pos patients, greater A1c decrease (−0.51% vs −0.28%) but similar weight loss and TDI were seen. Effect sizes for exenatide were similar, but studies had higher risk of bias and safety data were sparse.

Conclusion

Our meta-analysis supports therapeutic benefits of liraglutide for patients with T1DM mainly for weight loss and insulin dose reduction. Newly diagnosed or C-pos patients do not appear to experience greater weight loss benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2HumansGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlycated HemoglobinHypoglycemic AgentsInsulinLiraglutideVenomsWeight Loss

Stichwörter der Autor:innen

glucagon-like peptide 1 analoguesmeta-analysisnew-onset type 1 diabetes mellitustype 1 diabetes mellitusweight management

Substanzen

Glucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlycated HemoglobinHypoglycemic AgentsInsulinLiraglutideVenoms

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Health Sciences and Human Services Library, University of Maryland, Baltimore, MD 21201, USA.
  • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Central Ave, Hong Kong.
  • Lead Endocrinologist, Diabetes and Obesity Management Clinic, Chase Brexton Healthcare, Baltimore, MD 21201, USA.

ORCID-Profile: Jeayoung Park, Terry Cheuk-Fung Yip, Kashif M Munir, Nowreen Haq

Zitieren

APA

Park, J., Ntelis, S., Yunasan, E., Downton, K. D., Yip, T. C., Munir, K. M., & Haq, N. (2023). Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis. The Journal of Clinical Endocrinology & Metabolism, 109(1), 279-292. https://doi.org/10.1210/clinem/dgad471

Vancouver

Park J, Ntelis S, Yunasan E, Downton KD, Yip TC, Munir KM, et al. Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis. The Journal of Clinical Endocrinology & Metabolism. 2023;109(1):279-292. doi:10.1210/clinem/dgad471

BibTeX
@article{Park2023,
  author = {Park, Jeayoung and Ntelis, Spyridon and Yunasan, Elvina and Downton, Katherine D and Yip, Terry Cheuk-Fung and Munir, Kashif M and Haq, Nowreen},
  title = {Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {109},
  number = {1},
  pages = {279--292},
  doi = {10.1210/clinem/dgad471}
}
Kostenlos starten →